Zoll Medical Corporation, which received FDA clearance a few years ago for both home and hospital versions of its wearable defibrillator LifeVest, is now dealing with a range of lawsuits and FDA ...
81.7% of patients were on an SGLT2 inhibitor 74.7% of patients were on an ARNI 95.1% of patients were on a beta-blocker 83.1% of patients were on an MRA Despite high use of GDMT, the rate of ...
Medical device maker Zoll Medical Corporation has received FDA premarket approval for a wearable external defibrillator for use in the hospital. Zoll got approval last year for its LifeVest, a similar ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback